Check out the companies that are making news.
The energy giant signaled that it will report a fourth consecutive quarter of profit, thanks to stronger oil and gas prices. The snapshot of fourth quarter results came in an SEC filing.
The chipmaker said it would complete a $35 billion all-stock takeover of rival Xilinx in the first quarter of 2022, delayed from its previous year-end target. Some of the needed approvals have yet to be received. In the premarket, it was down 2%.
Paxlovid, the drug maker's Covid-19 antiviral pill, has been approved for use by British regulators for people over 18 with mild to moderate illness.
JMP Securities lowered the stock's rating to "market perform" from "market outperform", causing the stock to fall in premarket action. JMP says that website visits and page views are declining.
The exact ratio to be determined at a later date is what the medical technology company is planning to do with its reverse stock split. The company fell in premarket trading.
The maker of rare earth materials filed a shelf offering of up to $2 billion. The shares lost ground before the market opened.
The drug maker's shares surged 6.5% in premarket trading after it submitted a new drug application to the FDA for its heart drug sotagliflozin, which is designed to reduce the risk of heart failure in diabetics.
